Furthermore, when challenged with CD19- and CD22-targeted therapies, IKAROSlow tumor cells had the most survival advantage at lower effector-to-target ratios, conditions that resemble higher tumor burdens, and indicate a higher probability for IKAROSlow tumor cells to survive and enable antigen escape relapse. This evidence concerns the gene CD22 and neoplasm.